Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2019-09-25 Director's Dealing
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
DGAP-DD: Evotec SE english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'DGAP-DD: Evotec SE english' and contains the header 'Directors’ Dealings'. The content details transactions ('Details of the transaction(s)') made by a 'person discharging managerial responsibilities' (Dr. Cord Dohrmann, Member of the managing body). This directly matches the definition for Director's Dealing reports.
2019-09-25 English
DGAP-DD: Evotec SE english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a 'person discharging managerial responsibilities' (Dr. Werner Lanthaler, Member of the managing body). Section 4 details the nature, price, volume, and date of the transaction involving shares of Evotec SE. This directly corresponds to the definition of Director's Dealing (DIRS). The document format is a regulatory disclosure notification.
2019-09-25 English
DGAP-DD: Evotec SE english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: Evotec SE english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. This content directly relates to reporting personal share transactions by company directors and executives, which matches the definition for Director's Dealing (DIRS). The document details the person involved (Dr. Werner Lanthaler), their position, the nature of the transaction (Exercise against Cash Settlement linked to share option programmes), and the date/price.
2019-09-25 English
EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS
Regulatory Filings Classification · 100% confidence The document is a news release dated September 24, 2019, announcing a strategic, multi-year drug discovery collaboration between Evotec SE and Takeda Pharmaceutical Company Limited. It details the terms, including upfront payments, milestones, and royalties, and is disseminated via DGAP (a service often used for regulatory news in Germany). This type of announcement, detailing a significant business development (a major partnership/collaboration) that is not a standard financial report (like 10-K, IR, or ER), typically falls under general regulatory announcements or news releases. Since it is not a specific filing like a Director's Dealing (DIRS), Capital Change (CAP), or Earnings Release (ER), and it is a formal announcement of a business event, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate news releases not covered by more specific codes. It is not a proxy statement (PSI), management discussion (MDA), or a presentation (IP).
2019-09-24 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German securities law (WpHG). It details changes in the percentage of voting rights held by The Goldman Sachs Group, Inc. and its subsidiaries in Evotec SE, crossing specific thresholds (from 5.28% to 9.03%). This content directly corresponds to the definition of reporting changes in significant share ownership levels. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER: Not an earnings release. - DIV/CAP/SHA: Not primarily about dividends, financing, or general share issues. - DIRS: This is about director dealing, but this notification is from a major institutional shareholder (Goldman Sachs). - MRQ (Major Shareholding Notification): This category perfectly matches the content, which is a notification of a change in major shareholding/voting rights crossing a threshold (3% or more). Therefore, the classification is MRQ.
2019-09-11 English
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
Regulatory Filings Classification · 99% confidence The document is a short news release dated September 6, 2019, announcing that Evotec SE management will be presenting at several upcoming investor conferences between September 11 and October 2, 2019. This is not a full financial report (like 10-K or IR), nor is it a transcript, audit report, or dividend notice. It is an announcement about future investor engagement, which falls under general corporate news or investor relations updates. Since it details specific events where management will present, it is most closely related to Investor Presentation (IP) materials, but the document itself is just the *announcement* of attendance, not the presentation content. Given the options, this type of scheduling announcement is often categorized as a general Regulatory Filing (RNS) or sometimes related to Investor Presentations (IP) if the context implies the presentation material itself will be shared. However, since the core content is simply a schedule of conference attendance, and it is disseminated via DGAP (a service for regulatory announcements), the most appropriate general classification for an announcement of future investor events that isn't a specific report release is RNS, or potentially IP if we interpret it as pre-announcement for investor materials. Given the structure and the fact it's a brief news item about future events, RNS (Regulatory Filings/General Announcement) is the safest fallback, although it is highly relevant to investor relations. If 'Investor Presentation' (IP) is interpreted broadly to include announcements about investor meetings, that could fit, but RNS covers general corporate news dissemination well. I will classify it as RNS as it is a general corporate news announcement disseminated via a regulatory service (DGAP).
2019-09-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.